68621F110

Organogenesis Holdings Inc.

Could not find a ticker for this position, may be a filing error

A regenerative-medicine company that grows living skin and tissue grafts to help wounds heal. Its best-known product, Apligraf, was the first living cell-based skin substitute approved by the U.S. Food and Drug Administration, and its PuraPly line treats chronic wounds like diabetic ulcers. Founded in 1985 in Cambridge, Massachusetts, the company's name reflects its mission of growing organs and tissues in the lab.

Public Warrants to purchase Class A Common Stock (originally AHPAC SPAC warrants, became ORGOW; delisted from NASDAQ Jan 2019, expired Dec 10, 2023)